RS66070B1 - Bispecifična tetravalentna antitela i metode njihovog dobijanja i upotrebe - Google Patents

Bispecifična tetravalentna antitela i metode njihovog dobijanja i upotrebe

Info

Publication number
RS66070B1
RS66070B1 RS20241150A RSP20241150A RS66070B1 RS 66070 B1 RS66070 B1 RS 66070B1 RS 20241150 A RS20241150 A RS 20241150A RS P20241150 A RSP20241150 A RS P20241150A RS 66070 B1 RS66070 B1 RS 66070B1
Authority
RS
Serbia
Prior art keywords
antibody
egfr
binding
antibodies
cells
Prior art date
Application number
RS20241150A
Other languages
English (en)
Serbian (sr)
Inventor
Zeren Gao
phil Tan
Brian Kovacevich
Blair Renshaw
Jeffrey Adamo
Nga Sze Amanda Mak
Shi Zhuo
Lan Chen
Yi Zhu
Original Assignee
Systimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc filed Critical Systimmune Inc
Publication of RS66070B1 publication Critical patent/RS66070B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RS20241150A 2014-12-22 2015-12-19 Bispecifična tetravalentna antitela i metode njihovog dobijanja i upotrebe RS66070B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095348P 2014-12-22 2014-12-22
EP15874216.3A EP3237005B1 (en) 2014-12-22 2015-12-19 Bispecific tetravalent antibodies and methods of making and using thereof
PCT/US2015/066951 WO2016106157A1 (en) 2014-12-22 2015-12-19 Bispecific tetravalent antibodies and methods of makiing and using thereof

Publications (1)

Publication Number Publication Date
RS66070B1 true RS66070B1 (sr) 2024-11-29

Family

ID=56151464

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20241150A RS66070B1 (sr) 2014-12-22 2015-12-19 Bispecifična tetravalentna antitela i metode njihovog dobijanja i upotrebe

Country Status (22)

Country Link
US (2) US10919977B2 (OSRAM)
EP (3) EP4491195A3 (OSRAM)
JP (2) JP6947639B2 (OSRAM)
KR (4) KR102590385B1 (OSRAM)
CN (11) CN106659779B (OSRAM)
AU (1) AU2015369831B2 (OSRAM)
CA (2) CA2969867C (OSRAM)
DK (1) DK3237005T3 (OSRAM)
ES (2) ES2995733T3 (OSRAM)
FI (1) FI3237005T3 (OSRAM)
HR (1) HRP20241502T1 (OSRAM)
HU (1) HUE069256T2 (OSRAM)
IL (3) IL286835B2 (OSRAM)
LT (1) LT3237005T (OSRAM)
NZ (1) NZ732628A (OSRAM)
PL (1) PL3237005T3 (OSRAM)
PT (1) PT3237005T (OSRAM)
RS (1) RS66070B1 (OSRAM)
SG (1) SG11201704741PA (OSRAM)
SI (1) SI3237005T1 (OSRAM)
SM (1) SMT202400477T1 (OSRAM)
WO (2) WO2016106158A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2969867C (en) * 2014-12-22 2022-01-25 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
CN108948195B (zh) * 2017-05-23 2022-05-31 胡毅 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
JP7323513B2 (ja) * 2017-06-25 2023-08-08 システィミューン， インク． 抗４－１ｂｂ抗体とその作製及び使用方法
CA3069238A1 (en) * 2017-11-02 2019-05-09 Systimmune, Inc. Bispecific antibodies and methods of making and using thereof
US11708410B2 (en) 2018-01-15 2023-07-25 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against TIGIT
CN107974461A (zh) * 2018-01-18 2018-05-01 东北农业大学 一种高效表达anti-hEGFR基因的真核表达载体构建方法
CN108220244A (zh) * 2018-01-18 2018-06-29 东北农业大学 一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
KR20200143436A (ko) * 2018-04-13 2020-12-23 아피메트 게엠베하 Nk 세포 결합 항체 융합 구조체
CN112512575B (zh) * 2018-05-16 2024-08-06 嘉立医疗科技(广州)有限公司 双特异性抗体组合物及其使用方法
EP3833690B1 (en) 2018-08-08 2024-03-27 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Recombinant bifunctional protein targeting cd47 and her2
CN110850068B (zh) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 一种嵌合抗原受体亲和力检测方法
WO2020061376A2 (en) * 2018-09-19 2020-03-26 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
CN113301919B (zh) * 2018-11-13 2025-01-28 Jn生物科学有限责任公司 激活免疫细胞的双特异性抗体
CN114450306B (zh) * 2019-07-26 2024-04-05 Abl生物公司 抗egfr/抗4-1bb双特异性抗体及其用途
AU2020327000A1 (en) 2019-08-08 2022-03-31 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
CA3170338A1 (en) * 2020-02-19 2021-08-26 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
CN111548424A (zh) * 2020-06-05 2020-08-18 上海科弈药业科技有限公司 一种靶向egfr与cd47的多功能融合蛋白及其应用
WO2022061255A1 (en) * 2020-09-21 2022-03-24 Systimmune, Inc. Specificity enchanced bispecific antibody (seba)
IL311035A (en) * 2021-08-25 2024-04-01 Systimmune Inc TETRAVALENT BISPIFIC ANTIBODIES TARGETING EGFR AND HER3
US20250223376A1 (en) * 2021-09-20 2025-07-10 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023056485A1 (en) * 2021-10-03 2023-04-06 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof
KR20240101682A (ko) * 2021-11-15 2024-07-02 시스트이뮨, 인코포레이티드 이중특이 항체-캄프토테신 약물 접합체 및 이의 약학적 용도
WO2023241480A1 (zh) * 2022-06-13 2023-12-21 三优生物医药(上海)有限公司 抗pd-l1、vegf和egfr三特异性抗体及其应用
AU2023334288A1 (en) * 2022-08-31 2025-03-20 Systimmune, Inc. Biepitopic tetravalent antibody targeting egfr
CN116063564A (zh) * 2022-10-08 2023-05-05 盛禾(中国)生物制药有限公司 一种纯化融合蛋白的方法
WO2024168588A1 (en) * 2023-02-15 2024-08-22 Zhejiang Shimai Pharmaceutical Co., Ltd. Egfr and lag3 dual targeted bispecific antibody and uses thereof
TW202502823A (zh) * 2023-07-07 2025-01-16 大陸商四川科倫博泰生物醫藥股份有限公司 Ｅｇｆｒ／ｃ－ｍｅｔ雙特異性結合蛋白及其用途
WO2025026282A1 (en) * 2023-07-29 2025-02-06 Shanghai Kaijin Biotechnology, Ltd Modified type e multi-specific antibodies
WO2025117871A1 (en) * 2023-11-29 2025-06-05 Systimmune, Inc. Bispecific tetravalent antibody targeting her2 and her3
WO2025140662A1 (en) * 2023-12-29 2025-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/her3 antibodies and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2200753B (en) 1986-12-23 1991-01-23 Brookes & Gatehouse Speed measurement device
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2473144C (en) * 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
ZA200702427B (en) * 2004-09-17 2008-12-31 Domantis Ltd Compositions monovalent for CD40L binding and methods of use
MX2008015852A (es) * 2006-06-14 2009-02-23 Imclone Systems Inc Formulaciones liofilizadas de anticuerpos anti-egfr.
AU2007353412A1 (en) * 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
MA33198B1 (fr) * 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
JP2012521768A (ja) 2009-03-27 2012-09-20 ジモジェネティクス・インコーポレイテッド 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法
CN102369215B (zh) * 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
MX2011010166A (es) * 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
SG178602A1 (en) * 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5960598B2 (ja) * 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
EP2621532A1 (en) * 2010-09-30 2013-08-07 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her3 antibodies
CA2817448C (en) * 2010-12-23 2019-01-22 F. Hoffmann-La Roche Ag Binding agent
TWI838039B (zh) * 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
JP6177231B2 (ja) * 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
AU2012248470B2 (en) * 2011-04-25 2016-10-27 Daiichi Sankyo Company, Limited Anti-B7-H3 antibody
CN102250246A (zh) * 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN102250247B (zh) 2011-06-15 2013-06-19 常州亚当生物技术有限公司 一种抗vegf/ang2双特异性抗体及其应用
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
US8961971B2 (en) * 2011-12-22 2015-02-24 Development Center For Biotechnology Bispecific T-cell activator antibody
MX2014011500A (es) * 2012-03-27 2014-12-05 Genentech Inc Diagnosticos y tratamientos relacionados a inhibidores her3.
WO2014012082A2 (en) * 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
EP2922872B1 (en) * 2012-11-21 2018-10-10 Janssen Biotech, Inc. Bispecific egfr/c-met antibodies
CN104688740A (zh) * 2012-12-21 2015-06-10 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
JP2016514676A (ja) * 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
CN104211814A (zh) * 2013-05-29 2014-12-17 三星电子株式会社 用于消耗靶膜蛋白的组合物
CA2969867C (en) 2014-12-22 2022-01-25 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof

Also Published As

Publication number Publication date
CN113150165B (zh) 2024-09-03
AU2015369831B2 (en) 2019-07-11
KR20230104988A (ko) 2023-07-11
LT3237005T (lt) 2024-11-11
NZ732628A (en) 2019-01-25
CN113105552A (zh) 2021-07-13
CN106659779B (zh) 2021-05-18
US10919977B2 (en) 2021-02-16
IL286835B2 (en) 2024-03-01
ES2995733T3 (en) 2025-02-11
CN113105553B (zh) 2024-09-10
US20170073418A1 (en) 2017-03-16
KR20230149328A (ko) 2023-10-26
EP3237006A4 (en) 2018-05-30
CA3138083A1 (en) 2016-06-30
EP3237005A1 (en) 2017-11-01
EP3237005B1 (en) 2024-09-18
CN113105553A (zh) 2021-07-13
KR102823201B1 (ko) 2025-06-23
EP3237006A1 (en) 2017-11-01
SG11201704741PA (en) 2017-07-28
WO2016106158A1 (en) 2016-06-30
CN113105552B (zh) 2024-09-20
CA2969867A1 (en) 2016-06-30
CN113512122A (zh) 2021-10-19
EP3237005A4 (en) 2018-05-23
CN107206074A (zh) 2017-09-26
CN113105551B (zh) 2024-10-25
CN113105551A (zh) 2021-07-13
WO2016106157A1 (en) 2016-06-30
EP4491195A3 (en) 2025-04-02
CN113512121B (zh) 2024-10-25
IL286835B1 (en) 2023-11-01
CN106659779A (zh) 2017-05-10
CN113512120A (zh) 2021-10-19
CN113512123A (zh) 2021-10-19
FI3237005T3 (fi) 2024-12-02
CN117467017A (zh) 2024-01-30
ES2962675T3 (es) 2024-03-20
JP7335290B2 (ja) 2023-08-29
CA2969867C (en) 2022-01-25
AU2015369831A1 (en) 2017-06-29
CN113512123B (zh) 2024-10-25
IL305193A (en) 2023-10-01
JP6947639B2 (ja) 2021-10-13
CN113512120B (zh) 2024-08-02
PL3237005T3 (pl) 2025-01-27
US20170369587A1 (en) 2017-12-28
IL286835A (en) 2021-10-31
CN107206074B (zh) 2023-12-01
KR20250094744A (ko) 2025-06-25
KR20170091162A (ko) 2017-08-08
SI3237005T1 (sl) 2025-02-28
CN113512121A (zh) 2021-10-19
DK3237005T3 (en) 2024-11-18
JP2021119149A (ja) 2021-08-12
JP2018509175A (ja) 2018-04-05
PT3237005T (pt) 2024-11-18
IL252811B (en) 2021-10-31
EP4491195A2 (en) 2025-01-15
HUE069256T2 (hu) 2025-02-28
KR102548827B1 (ko) 2023-06-30
SMT202400477T1 (it) 2025-01-14
US10717783B2 (en) 2020-07-21
KR102590385B1 (ko) 2023-10-18
HRP20241502T1 (hr) 2025-01-03
EP3237006B1 (en) 2023-08-16
IL252811A0 (en) 2017-08-31
CN113150165A (zh) 2021-07-23
CN113512122B (zh) 2024-09-10

Similar Documents

Publication Publication Date Title
JP7335290B2 (ja) 二重特異性四価抗体並びにその製作及び使用方法
KR102593409B1 (ko) Her3 항원 결합 분자
CN108368170B (zh) 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CN116059347A (zh) 使用her3抗原结合分子治疗和预防癌症
CN113874399A (zh) 抗ror1/抗cd3双特异性结合分子
CN117946278A (zh) 多特异性抗体及其制备和使用方法
Zuo et al. A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding
US12428483B2 (en) Bispecific tetravalent antibodies and methods of making and using thereof
HK40120554A (en) Bispecific tetravalent antibodies and methods of makiing and using thereof
TW202146446A (zh) 一種抗pd-l1和egfr的四價雙特異性抗體
WO2016059068A1 (en) Vegfr-2 binding polypeptides
TWI899079B (zh) 抗ror1/抗cd3雙特異性結合分子
HK1233941A1 (en) Bispecific tetravalent antibodies and methods of making and using thereof
HK1233941B (zh) 双特异性四价抗体及其制造和使用方法